Lotus Pharmaceutical Co Ltd (1795) — Capital Reinvestment Ratio
Lotus Pharmaceutical Co Ltd (1795) has a Capital Reinvestment Ratio of 1.19x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$1.35 Billion) in capital expenditures (NT$1.60 Billion). See how leveraged is Lotus Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Lotus Pharmaceutical Co Ltd Capital Reinvestment Ratio (2009–2025)
This chart tracks Lotus Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 13 annual periods. Check Lotus Pharmaceutical Co Ltd (1795) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd (2009–2025)
Year-by-year Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd from 2009 to 2025. For live market cap and broader valuation context, see 1795 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.58x | NT$7.48 Billion | NT$4.35 Billion | ▲ +144.4% |
| 2024 | 0.24x | NT$6.15 Billion | NT$1.47 Billion | ▼ -88.3% |
| 2023 | 2.03x | NT$1.61 Billion | NT$3.28 Billion | ▲ +1207.5% |
| 2022 | 0.16x | NT$3.72 Billion | NT$577.16 Million | ▼ -98.9% |
| 2021 | 13.50x | NT$119.66 Million | NT$1.62 Billion | ▲ +1217.2% |
| 2020 | 1.03x | NT$1.95 Billion | NT$2.00 Billion | ▼ -71.9% |
| 2019 | 3.64x | NT$302.81 Million | NT$1.10 Billion | ▲ +627.3% |
| 2018 | 0.50x | NT$796.98 Million | NT$399.07 Million | ▼ -67.6% |
| 2017 | 1.54x | NT$592.29 Million | NT$914.84 Million | ▲ +188.3% |
| 2016 | 0.54x | NT$1.23 Billion | NT$660.48 Million | ▲ +10.9% |
| 2015 | 0.48x | NT$1.08 Billion | NT$520.71 Million | ▼ -80.6% |
| 2010 | 2.49x | NT$59.19 Million | NT$147.57 Million | ▲ +786.5% |
| 2009 | 0.28x | NT$89.50 Million | NT$25.17 Million | — |